Provided herein are epidermal microfluidic systems and methods that allow for the collection of biofluids in a wet or aquatic environment, for example, from the surface of the skin. The described systems allow for the efficient collection of biofluids, without loss of the biofluid to the surrounding environment or introduction of extraneous liquids from the environment. The described microfluidic systems are versatile and can provide information regarding a number of biofluid properties both electronically and colorimetrically/visually.

Methods for determining the presence of pathologic amylin in a subject with diabetes or pre-diabetes are provided herein. The method includes obtaining a skin sample from a subject and determining if there is pathologic amylin present in the skin sample.

This present application generally relates to methods and systems that allow for the establishment of personalized skin care regimen for an individual based upon the individual's genetic profile comprising biomarkers genetically associated with skin phenotypic attributes and/or skin nutritional conditions. In particular, kits and methods are disclosed for determining an individual's genetic profile, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based at least in part on the biomarkers used, weights applied thereto, and the resulting likelihood of the individual to exhibit a plurality of skin phenotypic attributes. Such a personalized skin care regimen is advantageous as compared to traditional skin care programs.

The present invention is related to novel methods for identifying a population of subjects that are at risk for developing of atopic allergic diseases, and to the prevention of these allergic diseases.

The invention generally features compositions and methods for characterizing atopic dermatitis as responsive to anti-Thymic Stromal Lymphopoietin (TSLP) therapy by detecting alterations in the levels of polypeptide and polynucleotide markers present in patient samples, and related treatment methods.

The present invention refers to an in vitro method to determine if the skin of a subject presents signs of physiological aging, a method of cosmetic and a method to identify a substance that is capable of reducing or reversing the visible signs of physiological skin aging. The invention further refers to a kit comprising capture ligands and a use of said kit for determining in a skin sample the expression level of the markers of skin aging that are identified in context of the present invention.

Provided herein is a method of sorting human dermal fibroblasts, comprising (a) providing a cell population comprising human dermal fibroblasts; and (b) separating the human dermal fibroblasts into subpopulations based on expression of one or more cell-surface markers selected from CD39, CD36 and CD26. Also provided are isolated populations of human dermal papillary fibroblasts and cosmetic and therapeutic uses thereof.

Provided herein are epidermal microfluidic systems and methods that allow for the collection of biofluids in a wet or aquatic environment, for example, from the surface of the skin. The described systems allow for the efficient collection of biofluids, without loss of the biofluid to the surrounding environment or introduction of extraneous liquids from the environment. The described microfluidic systems are versatile and can provide information regarding a number of biofluid properties both electronically and colorimetrically/visually.

Systems and methods for generating user-specific recommendations of products or services by collaborative filtering executed and/or performed by one or more trained or untrained predictive models configured to ingest product attribute(s), product purpose(s), user location data, and/or user demographics. The predictive model(s) are leveraged to detect and determine user-specific preferences for, and preferences against, particular attributes, features, ingredients, aesthetic styles, and so on.

The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.